Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew Mertz

Podiatrist, Foot Surgery Lehighton, PA Doctor of Podiatric Medicine

NPI 1780786277 CMS profile 307560

215 S 1St St, Lehighton, PA 18235

Open in the dashboard

General payments

$951

28 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Mertz of Lehighton, PA is reported in the CMS Open Payments database as having received $951 across 28 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 55th percentile of Podiatrist, Foot Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $50 3
2024 General $75 4
2023 General $216 13
2022 General $373 6
2021 General $124 1
2019 General $113 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Mertz
  • Podiatrist, Foot Surgery median
  • Middle half of Podiatrist, Foot Surgery
  • National median

In program year 2025, general payments to Matthew Mertz were reported at $50. Among 732 Podiatrist, Foot Surgery profiles paid that year, the median was $180 and the middle half received between $70 and $569.

Show as a table
Year Matthew Mertz Podiatrist, Foot Surgery median Middle half National median
2019 $113 $167 $67–$484 $163
2020 $0 $114 $40–$323 $114
2021 $124 $171 $57–$502 $132
2022 $373 $196 $66–$556 $149
2023 $216 $187 $78–$466 $160
2024 $75 $190 $78–$557 $164
2025 $50 $180 $70–$569 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GRT US Holding, Inc. $373 6 payments
  2. Stryker Corporation $237 2 payments
  3. Averitas Pharma Inc. $235 14 payments
  4. Next Science LLC $44 2 payments
  5. Paratek Pharmaceuticals, Inc. $43 3 payments
  6. Smith+Nephew, Inc. $20 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $951 28 payments
Products named General payments · program years 2019–2025
  1. Qutenza $608 20 payments
  2. AUGMENT INJECTABLE $124 1 payment
  3. ALLOWRAP $113 1 payment
  4. SurgX $44 2 payments
  5. Xperience $44 2 payments
  6. BlastX $44 2 payments
  7. NUZYRA $43 3 payments
  8. PICO $20 1 payment
  9. RENASYS GO v2 HOME $20 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

204

Median for Podiatry: 160

Drug cost

$2,368

Median for Podiatry: $2,368

Branded share of claims

0%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 93 $930
Ketoconazole Generic 24 $719
Cephalexin Generic 31 $280
Methylprednisolone Generic 34 $262
Mupirocin Generic 22 $177

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 54 billing codes

Paid by Medicare

$405,622

Of which drugs: $57,134

Medicare patients

1,247

Average age 80

Services billed

32,879

776 women, 471 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Chronic kidney disease 51%
Diabetes 45%
Depression 40%
Alzheimer's or dementia 36%
Ischemic heart disease 34%
Heart failure 30%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Capsaicin 8% patch, per square centimeter J7336 Office 11 22,400 $56,936
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 39 234 $174
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 40 268 $23

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qutenza
  • Averitas Pharma Inc. $46
$46 — 22,400
NUZYRA
  • Paratek Pharmaceuticals, Inc. $29
$29 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

28 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot Surgery in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record